Carlo Vancheri
Professor Vancheri’s research is mainly focused on interstitial lung disease, specifically pathogenesis of idiopathic pulmonary fibrosis (IPF) and preclinical studies addressed to the identification of new molecules in the treatment of pulmonary fibrosis. Viewing IPF as a cancer-like disease may satisfy the need for a better understanding of the pathogenesis of IPF by exploiting the large amount of knowledge that cancer biology evokes. Professor Vancheri’s clinical interest is focused on the recognition of common pathogenic pathways between the two diseases that may stimulate new clinical trials with cancer drugs, different drug combinations and different lines of drugs, as already experimented in oncology. His research activities are mainly addressed to the study of the pathogenesis of pulmonary fibrosis and the identification of new approaches in the treatment of pulmonary fibrosis.
KEYWORDS:
FIBROSIS – LUNG - IDIOPATHIC - FIBROBLASTS - CANCER - PATHOGENESIS - PROTEOMIC - EPIGENETIC
RESEARCH PROJECTS:
EUROPEAN RESEARCH
SEVENTH FRAMEWORK PROGRAMME FOR RESEARCH AND TECHNOLOGICAL DEVELOPMENT 2007-2013
Project reference: 202224.
In the eurIPFnet consortium, leading European basic and clinical scientists in the field of interstitial lung diseases associate to jointly decipher the natural course and molecular pathomechanisms of Idiopathic Pulmonary Fibrosis (IPF) and to develop new therapeutic strategies for patients with IPF. Our translational research programme includes implementation of a European IPF registry (eurIPFreg), in which data with regard to natural course, familiar background and susceptibility factors of IPF will be collected, and of a European IPF biobank (eurIPFbank) of blood, bronchoalveolar lavage fluid, cells and tissue specimen of IPF.
Project Coordinator: Justus-Liebig-Universitaet Giessen, Germany
Cfr: European IPF Registry (eurIPFreg)
NATIONAL AND REGIONAL RESEARCH PROGRAMMES
EU STRUCTURAL FUNDS 2007-2013
[2013-2015]
Piattaforma regionale di ricerca traslazionale per la salute
Pon Conv Fesr Ricerca e Competitività - CUP: B65E12000570008
Project website - Projetc leader: Università degli Studi di Palermo
PRIVATELY FUNDED RESEARCH
[2015-2016]
Molecular mechanism of pro-apoptotic effects in Nintedanib (BIBF 1120) in human fibrotic lung fibroblasts
Sponsor: Boehringer Ingelheim Int.GmbH.
[2012-2014]
Molecular characterization of Pirfenidone antifibrotic effects in human lung cells
Sponsor: InterMune Inc.
[2013-2014]
Putative pro-apototic properties of Nintedanib in human lung fibroblasts
Sponsor: Boehringer Ingelheim Int.GmbH.
[2012-2013]
Valutazione in vitro del potenziale terapeutico di formulazioni inalatorie contenenti Carnosina ed altre sostanze anti-ossidanti sul trattamento della fibrosi polmonare
Sponsor: Eratech s.r.l.
Referee activities for this scientific journals
- American Journal of Respiratory and Critical Care Medicine
- European Respiratory Journal
- Respiratory Medicine
- Sarcoidosis
- Respiratory Research
Editor for this scientific journals
Prevenzione respiratoria, organo ufficiale della Federazione Italiana contro le Malattie Sociali e la Tubercolosi
Ars Pneumologica
Principal Investigator in phase II and III international clinical trials
International Scientific Consultant for pharmaceutical companies
Visiting Professor (University Diderot Paris)
Member of the Committee of the biomedical district of Sicily
President of the Scientific Committee RespiRARE, Onlus association for Rare Lung Diseases.
Director of the Referral Centre for Rare Lung Diseases